NEWSROOM
Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital co-leads €164.5 million ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development of Anti-Claudin-1 (CLDN1) ADCs in solid tumors
Building on its co-lead investments in Alentis Therapeutics’ Series B (2021) and Series C (2023) rounds, Jeito’s renewed commitment demonstrates its strategy of supporting promising portfolio companies through key value-creation milestones. Financing will advance...
Find all our press releases
Jeito Capital participates in a $95 Million financing for HI-Bio™, a US-based clinical-stage biopharma company developing targeted therapies for patients with severe immune-mediated diseases
One year after its first investment, this new significant participation in HI-Bio™’s Series B...
Jeito Capital announces appointment of new Partner Investor Ksenija Pavletic
Paris, France, 3 January 2024 - Jeito Capital ("Jeito"), a global leading independent private...
Jeito Capital portfolio company Advesya emerges from stealth mode with the potential to become a leader in the treatment of hematological malignancies and other tumor treatments
Paris, France, 3 January 2024 - Jeito Capital ("Jeito"), a global leading independent private...
Jeito Capital creates a community of leading international Special Advisors to complement its extensive sets of skills and further extend its support to portfolio companies
Paris, France, November 29th 2023 - Jeito Capital (“Jeito”), a leading global investment company...
Jeito Capital leads €75 million Series B Financing in NMD Pharma, a Danish company, to develop breakthrough treatments for patients with severe neuromuscular diseases
Jeito Capital’s second round of funding will support NMD Pharma in becoming a leading, global,...
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
EyeBio doubles the size of its original Series A raise with an additional $65 million, with new...
Face to face
Meet Jeito
16-17
December
All day long
Conference of Paris 2024
Jeito will be present at the Conference of Paris 2024, for its 8th edition around the theme “Confronting the Unknown”, encouraging leaders to share their knowledge and understanding of global economic, social and environmental issues as a way to collaborate and collectively overcome these challenges.
13-16
January
All day long
JPM Healthcare Conference 2025
Jeito will be present at the 43rd JPM Healthcare Conference 2025, renowned as the largest and most influential healthcare investment symposium, attracting global industry leaders, Biotech companies, and members of the investment community, in San Francisco.
28-30
January
All day long
IPEM Cannes 2025
Jeito will be present at the 11th edition of IPEM Cannes – Wealth 2025, gathering Private Capital key decision-makers and incubating this year “IPEM Wealth”, a brand-new format designed to support the democratization of Private Markets, in Cannes.